Lisa Wolfe, MD
Pulmonary Disease · Chicago, ILNPI 1336166800
Payments from drug & device makers
What this record shows
Merck accounts for 61.9% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $2,099 and has fallen 92.2% since, to $164 in 2025.
Across 28 payments — averaging $94.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- Fisher & Paykel Healthcare Inc$347
- Philips North America LLC$165
- Biogen$118
- Sanofi$96
- Sunovion Pharmaceuticals Inc.$95
- plus $185 from 5 others
Across 12 payments — averaging $9368.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Hill-rom Company, Inc$92K
- Baxter Healthcare$17K
- Advanced Respiratory, Inc$4K
What the payments were for
- Travel & lodging$1,37552%
- Food & beverage$1,26548%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 7 | $1,635 |
| Fisher & Paykel Healthcare Inc | 5 | $347 |
| Philips North America LLC | 3 | $165 |
| Biogen | 1 | $118 |
| Sanofi | 1 | $96 |
| Sunovion Pharmaceuticals Inc. | 5 | $95 |
| Advanced Respiratory, Inc | 1 | $47 |
| 3b Medical, Inc. | 1 | $46 |
| Hill-rom Company, Inc | 1 | $39 |
| GSK | 2 | $36 |
| Optinose US, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Obstructive Sleep Apnea Device or Hospital Respiratory Equipment$206
- QALSODY$118
- Mask$115
- NightBalance Und$115
How this compares
$2,641 in reported general payments places this provider in the 55th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymbicortBudesonide/Formoterol Fumarate | 16 | $5,403 |
| Modafinil | 44 | $3,466 |
| Eszopiclone | 32 | $2,205 |
| Ipratropium Bromide | 64 | $1,903 |
| Gabapentin | 57 | $1,100 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $805 |
| Pregabalin | 13 | $631 |
| Azelastine Hcl | 27 | $569 |
| Glycopyrrolate | 17 | $566 |
| Baclofen | 21 | $461 |
| Montelukast Sodium | 27 | $374 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $368 |
| Clonazepam | 35 | $338 |
| Lorazepam | 13 | $328 |
| Trazodone Hcl | 17 | $300 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Chicago
- Douglas HogarthChicago$2.9M
- Steven WhiteChicago$970K
- Momen WahidiChicago$779K
- Septimiu MurguChicago$633K
- Ayodeji AdegunsoyeChicago$561K
- Ravi KalhanChicago$375K
- Brian GaribaldiChicago$356K
- Manu JainChicago$187K
- Richard WunderinkChicago$178K
- Rade TomicChicago$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.